Obesity Or Overweight
KLRAKailera TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for Ribupatide Injection (KAI-9531) (GLP-1/GIP Agonist) in Obesity Or Overweight. The expected timing is based on the latest available company guidance and may change.
KaiNETIC program. 05/26/26:- KaiNETIC Ph3 began. Ph2b data 2027; Ph3 data 2028. Ph1 data reported on June 5, 2026. 06/05/26:- NCT07044401 Ph1 SAD injection data showed up to 5.5% loss Day 29; KaiNETIC global Ph3 ongoing. 08/12/26:- NCT07458269 U.S. Ph2b high-dose trial fully enrolled; data is anticipated Mid-2027. KaiNETIC Ph3 data is anticipated in 2028.
Verification
Confirm timing and program details against the company announcement or filing.